{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:53:02Z","timestamp":1777891982743,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Respir Care"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:p>Pharmacologic agents to promote mucus clearance may reduce the sequelae of obstructive secretions. We systematically reviewed comparative studies of pharmacologic agents for mucus clearance in hospitalized or postoperative subjects without cystic fibrosis and over 12 months of age. We searched MEDLINE and other databases from January 1970 to July 2014 to identify relevant literature. Two reviewers independently assessed each study against predetermined inclusion\/exclusion criteria. Two reviewers also independently extracted data regarding subject and intervention characteristics and outcomes and assigned overall quality ratings. The 9 studies meeting review criteria included 5 randomized controlled trials, 3 crossover randomized controlled trials, and one retrospective cohort study. Studies were small and together included a total of 379 subjects (mean of 42 subjects per study). N-acetylcysteine, heparin plus N-acetylcysteine, albuterol, ipratropium bromide, and saline were assessed. Studies reported no benefit of studied agents on expectoration, pulmonary function, and atelectasis and little effect on changes in sputum volume, weight, or viscosity. Adverse effects of agents were not consistently reported. Nausea was reported in 2 studies of N-acetylcysteine (one paper reported 2 experiments and did not clearly identify in which experiment adverse effects occurred), 3 studies reported that there were no adverse events, and 3 studies did not address adverse effects at all. Further research with clearly characterized populations and interventions is needed to understand the potential benefits and adverse effects of mucoactive agents.<\/jats:p>","DOI":"10.4187\/respcare.04086","type":"journal-article","created":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T22:51:19Z","timestamp":1430866279000},"page":"1061-1070","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Pharmacologic Agents That Promote Airway Clearance in Hospitalized Subjects: A Systematic Review"],"prefix":"10.1177","volume":"60","author":[{"given":"Nila A","family":"Sathe","sequence":"first","affiliation":[{"name":"Vanderbilt Evidence-based Practice Center, Institute for Medicine and Public Health"},{"name":"Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanthi","family":"Krishnaswami","sequence":"additional","affiliation":[{"name":"Vanderbilt Evidence-based Practice Center, Institute for Medicine and Public Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Andrews","sequence":"additional","affiliation":[{"name":"Vanderbilt Evidence-based Practice Center, Institute for Medicine and Public Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Ficzere","sequence":"additional","affiliation":[{"name":"Christy Houston Foundation Drug Information Center, Belmont University College of Pharmacy, Nashville, Tennessee."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa L","family":"McPheeters","sequence":"additional","affiliation":[{"name":"Vanderbilt Evidence-based Practice Center, Institute for Medicine and Public Health"},{"name":"Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,7,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.07521176"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00003510"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.10.014"},{"issue":"4","key":"e_1_3_3_5_2","first-page":"425","article-title":"Role of N-acetylcysteine in the management of COPD","volume":"1","author":"Sadowska AM","year":"2006","unstructured":"Sadowska AM, , Verbraecken J, , Darquennes K, , De Backer WA. Role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis, 2006; 1(4):425\u2013434.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2006.04.198"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.07520859"},{"key":"e_1_3_3_8_2","first-page":"139","article-title":"Clinical issues of mucus accumulation in COPD","volume":"9","author":"Ramos FL","year":"2014","unstructured":"Ramos FL, , Krahnke JS, , Kim V. Clinical issues of mucus accumulation in COPD. Int J Chron Obstruct Pulmon Dis, 2014; 9:139\u2013150.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.02704"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.09540522"},{"issue":"5","key":"e_1_3_3_11_2","first-page":"301","article-title":"Prevention of postoperative pulmonary atelectasis: review of 215 cases and evaluation of acetylcysteine","volume":"32","author":"Thomas PA","year":"1966","unstructured":"Thomas PA, , Lynch RE, , Merrigan EH. Prevention of postoperative pulmonary atelectasis: review of 215 cases and evaluation of acetylcysteine. Am Surg, 1966; 32(5):301\u2013307.","journal-title":"Am Surg"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.1.124"},{"issue":"8","key":"e_1_3_3_13_2","first-page":"485","article-title":"A controlled study of the safety and efficacy of acetylcysteine-isoproterenol combination","volume":"12","author":"Pulle DF","year":"1970","unstructured":"Pulle DF, , Glass P, , Dulfano MJ. A controlled study of the safety and efficacy of acetylcysteine-isoproterenol combination. Curr Ther Res Clin Exp, 1970; 12(8):485\u2013492.","journal-title":"Curr Ther Res Clin Exp"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004630-199805000-00004"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1977.tb00771.x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.1989.tb02894.x"},{"issue":"2","key":"e_1_3_3_17_2","first-page":"103","article-title":"Effects of N-acetylcysteine on asthma exacerbation","volume":"9","author":"Aliyali M","year":"2010","unstructured":"Aliyali M, , Poorhasan Amiri A, , Sharifpoor A, , Zalli F. Effects of N-acetylcysteine on asthma exacerbation. Iran J Allergy Asthma Immunol, 2010; 9(2):103\u2013109.","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-4-13"},{"key":"e_1_3_3_19_2","first-page":"CD001289","article-title":"Mucolytics for bronchiectasis","volume":"5","author":"Wilkinson M","year":"2014","unstructured":"Wilkinson M, , Sugumar K, , Milan SJ, , Hart A, , Crockett A, , Crossingham I. Mucolytics for bronchiectasis. Cochrane Database Syst Rev, 2014; 5:CD001289.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_20_2","first-page":"CD001287","article-title":"Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease","volume":"8","author":"Poole P","year":"2012","unstructured":"Poole P, , Black PN, , Cates CJ. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2012; 8:CD001287.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_21_2","first-page":"CD009769","article-title":"Beclometasone for chronic obstructive pulmonary disease","volume":"10","author":"De Coster DA","year":"2013","unstructured":"De Coster DA, , Jones M, , Thakrar N. Beclometasone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2013; 10:CD009769.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Respiratory Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.4187\/respcare.04086","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4187\/respcare.04086","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4187\/respcare.04086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:15:08Z","timestamp":1777616108000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.4187\/respcare.04086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.4187\/respcare.04086"],"URL":"https:\/\/doi.org\/10.4187\/respcare.04086","relation":{},"ISSN":["0020-1324"],"issn-type":[{"value":"0020-1324","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}